. Adiponectin values were a significant predictor for amyloidosis (AUC 0.75, p<0.03) 
Introduction
The autoinflammatory disorders (AIDs) are a group of diseases of the innate immune system characterised by unprovoked recurrent attacks of fever with localised inflammation that can affect multiple organ systems. AIDs are caused by mutations of genes which are involved in the regulation and/or activation of the inflammatory response (1) . Tumour necrosis factor (TNF) receptorassociated periodic syndrome (TRAPS) is the most common autosomal dominant autoinflammatory disorder and is caused by mutations in the TNFRSF1A gene encoding the 55-kD receptor for TNF-α (TNFRSF1A), a transmembrane glycoprotein that consists of an extracellular domain comprising 4 tandem repeat cystein-rich domains (CRD1-4), a transmembrane region and an intracellular death domain (2) . TNFRSF1A extracellular domain mutations negatively affect both TNFRSF1A expression and function (2) (3) (4) . The majority of mutations is localised in the CRD1 and CRD2 domains, in fact most mutations described involve cysteine residues and are associated with a higher disease penetrance (5) . Characteristic features of TRAPS include recurrent fever, lasting typically more than 1 week, periorbital oedema, a migratory erythaematous plaque with underlying myalgia and arthralgia; serosal membrane inflammation is also possible (6) (7) (8) . Amyloidosis is the most serious long-term complication of TRAPS, and occurred in about 25% of patients in prebiological era (9) . Patients carrying mutations involving cysteine residues may be younger at disease onset and suffer more prolonged and frequent fever attacks (10) , thus demonstrating a higher severity of their clinical phenotype; these patients are currently considered to be at higher risk of developing life-threatening AA amyloidosis (9) . White adipose tissue produces more than 50 adipokines and other molecules that participate through endocrine, paracrine, autocrine or juxtacrine mechanisms of action in a wide variety of physiopathological processes, including food intake, insulin sensitivity, vascular sclerotic processes, immunity and inflammation (11) (12) (13) . Among the adipokines known to be secreted by adipose tissue, tumour necrosis factor (TNF)-α, interleukin (IL)-6, leptin, resistin and visfatin are considered to be pro-inflammatory, whereas adiponectin has been described to have anti-inflammatory as well as pro-inflammatory properties depending on its molecular form (14) . It has been demonstrated that these adipokines can play a fundamental role in inflammatory rheumatological autoimmune diseases (12, 13, 15, 16) , and that in several rheumatic diseases, they are often associated with increased cardiovascular risks (17) . To date, with regard to AIDs, serum adipokines have been evaluated only in familial Mediterranean fever (FMF), the most common autosomal recessive disorder (18) (19) (20) (21) . The aims of our study were to evaluate serum leptin, resistin, visfatin and adiponectin levels in patients with TRAPS, in comparison to healthy controls, and also to correlate their serum levels to parameters of disease activity and/or disease severity. Six out of 14 Group 1 patients were receiving corticosteroids (7.5-17.5 mg/daily of prednisone), 2/14 were treated with the recombinant human IL-1 receptor antagonist anakinra (100 mg/daily) and 1/14 was treated with the TNF-α neutralising agent etanercept (50 mg once a week). Seven out of 16 Group 2 patients were receiving corticosteroids (7.5-12.5 mg/daily of prednisone), 2/16 were treated with anakinra (100 mg/daily), 1/16 with methotrexate (10 mg/daily), 1/16 with etanercept (50 mg/weekly), and 3/16 were receiving colchicine (1mg/daily). The remaining patients were not receiving any medication. Informed consent was obtained both from the patients and from the healthy controls, in accordance with the local ethics committee regulations.
Patients and methods

Patients
Assessment parameters
Assessment parameters included: gender, BMI, age, age at disease onset, duration of fever episodes, number of fever episodes/year, amyloidosis (presence/absence). 
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Laboratory assessments
Blood samples from TRAPS patients were collected during fever-free and symptom-free intervals. Blood samples (6 ml) were drawn from an antecubital vein with the patient in the supine position in the morning after an overnight fast. The blood was immediately centrifuged and serum was stored at -80°C until analysed. Serum leptin levels were detected with the enzyme-immunoassay method using Leptin (human) EIA Kit (Alexis assay designes/Enzo life Sciences). Sensitivity of samples was 23.4 pg/ml. Inter-and intra-assay coefficients of variation were 3.7-15.2% and 4.4-13.4%, respectively. Serum resistin levels were detected with the enzyme-linked immunosorbent assay method using Resistin (human) Elisa kit (AdipoGen Inc., Korea). Sensitivity of samples was 100 pg/ ml. Inter-and intra-assay coefficients of variation were 4.2-7.2% and 2.8-5.2%, respectively. Serum visfatin levels were detected with the enzyme-linked immunosorbent assay method using Nampt(Visfatin/PBEF)(human) Elisa kit (AdipoGen Inc., Korea). Sensitivity of samples was 30 pg/ml. Inter-and intra-assay coefficients of variation were 4.7-7.2% and 2.3-9%, respectively. Serum adiponectin levels were determined with the enzyme-linked immunosorbent assay method using Adiponectin (human) Elisa kit (AdipoGen Inc., Korea). Sensitivity of samples was 100 pg/ml. Inter-and intra-assay coefficients of variation were 2.8-5.5% and 2.9-3.8%, respectively. Other laboratory assessment parameters included: a) erythrocyte sedimentation rate (ESR), b) C-reactive protein (CRP), c) serum amyloid A (SAA). SAA serum concentration was determined with a commercial solid phase sandwich Enzyme linked-immunosorbent assay (ELISA) (Human SAA, BioSource Europe S.A., Belgium). The assay sensitivity was <4 ng/ml. The normal value of SAA was <6.4 mg/l. ESR was measured using the Westergren method. Values are expressed in mm/hour. An ESR <15 mm/hour was considered to be normal for males and an ESR <20 mm/hour was considered to be normal for females. Serum CRP concentrations were measured using a nephelometric immunoassay. Values are expressed in mg/dl. A CRP <0.5 mg/dl was considered to be normal.
Statistical analysis
All results are expressed as mean ± standard deviation (SD) or median (range). Mann-Whitney U-test, with Fisher's exact test, when appropriate, and analysis of covariance (ANCO-VA) with least significant difference (LSD) correction were used to evaluate the mean differences (±SD) between groups, considering the following covariates for ANCOVA: gender, age, age at disease onset, age at the time of collecting sample, weight, height, BMI, SAA levels, ESR, CRP, the presence/ absence of amyloidosis, the number of attacks/year, the duration of the fever attacks, entered as days, and treatment (steroids and biological modifier drugs) at the time of serum sample collection. The Spearman rank correlation test was used to determine correlation coefficients between the four adipokines serum levels and the above reported entered variables, including the type of identified mutation. Multiple stepwise regression was performed to determine variables, including demographic variables, that could correlate independently; the predictors used in the final model were those showing a significant correlation in the univariate analysis. A receiver operating characteristic curve (ROC) was constructed for determination of optimal cut-off values of adiponectin for predicting the development of amyloidosis. Non-parametric tests were used, where necessary, due to the small size of our groups and to the skewness of our data. Levels of p<0.05 were considered statistically significant. Analyses were performed on SPSS package for Windows, version 13.0 (SPSS, Inc., Chicago, IL, USA).
Results
The three groups were homogeneous for the following reported demographic variables: gender, age at enrollment, weight, height, and BMI. Group 1 and Group 2 showed significant differences regarding age at disease onset (p<0.004), the number of attacks/year (p<0.04), the duration of fever attacks (p<0.003), and the presence/absence of amyloidosis (p<0.05) ( Table I) . Serum leptin, resistin and adiponectin did not significantly differ among the 3 groups. Conversely, visfatin serum levels resulted significantly different between the 3 groups (p=0.02). In fact, serum visfatin levels were lower in Group 1 patients in comparison to Group 2 patients (1.48±0.95 pg/ml vs. 3.54±2.88 pg/ml, p<0.008); no difference was instead detected regarding controls (Table II) (Fig. 1) (Fig.3) . ROC analysis was used to examine the diagnostic accuracy of adiponectin serum levels to discriminate patients with and without amyloidosis. The area under the ROC curve (AUC) was 0.75 (95 CI: 0.56-0.94), thus resulting adiponectin values were a significant predictor for amyloidosis (p<0.03). The optimal cut-off value for predicting amyloidosis was set at 23.16 pg/ml; serum adiponectin levels >23.16 had a sensitivity of 87.5% (7/8), and a specificity of 77.3% (5/22), with a predictive positive value of 53.8% (7/13 
Discussion
In recent years, scientific interest in adipose tissue-derived peptides has increased dramatically since several mediators known as adipokines such as leptin, resistin, visfatin and adiponectin have been shown to play a relevant role in systemic inflammation (11) . AIDs are typical systemic inflammatory conditions (1). In this study, we investigated whether baseline serum levels of leptin, resistin, visfatin and adiponectin are increased in patients with TRAPS versus healthy controls and, in addition, we also investigated whether such patient serum levels significantly correlated with parameters of disease activity and/or disease severity. Serum leptin, resistin and adiponectin levels were not increased in TRAPS patients versus healthy controls, nor in patients carrying mutations known to be associated with a higher disease penetrance or in patients carrying other mutations. On the contrary, serum visfatin levels were significantly lower in patients carrying mutations involving cysteine residues in comparison to patients carrying non-cysteine mutations. However, serum leptin levels significantly correlated with the number of fever attacks/year, and patients carrying mutations involving cysteine residues, who showed more frequent attacks of fever, had higher levels of serum leptin compared to the patients carrying other mutations. Resistin and visfatin did not show any significant correlation, while serum adiponectin levels significantly correlated with the presence of amyloidosis. No significant correlation was found between serum adipokines levels and steroid treatment or biologic modifier drugs. Toy et al. demonstrated that, among AIDs, serum leptin levels do not increase during FMF fever attacks, and leptin proved not to be useful for diagnostic purposes and follow-up during treatment (18) . However, serum resistin level does significantly increase during FMF fever attacks, while visfatin serum levels provide no information either during attacks or for attack-free periods (19) . In addition, recent data have shown that adiponectin serum levels increase during FMF attacks and down-regulate during symptom-free intervals (20, 21) . These findings suggest that different chronic autoinflammatory disorders may show different serum adipokines patterns. FMF is a chronic inflammatory disorder and preliminary studies suggest that its attack-free periods are characterised by subclinical inflammation and associated endothelial dysfunction, increased atherosclerotic burden and platelets activation. However, increased atherosclerosis, than that in the general population, was not observed in patients with FMF (22) . In most studies it has been speculated that colchicine therapy is responsible for a less aggressive course of atherogenesis (23) .
Visfatin is an insulin-mimetic adipokine that was originally discovered in liver, skeletal muscle and bone marrow as a growth factor for B lymphocyte precursors (whence its alternative name, pre-B-colony enhancing factor, or PBEF) (17) . Li et al. have recently shown that tumour necrosis factor (TNF)-α acts directly on adipocytes, thus down regulating visfatin serum levels through activation of TNFRSF1A (24) . In patients with TRAPS, TNF-α serum levels may not increase (25) , however the altered TNFRSF1A activity might be responsible for lowering serum visfatin levels as we shown in patients carrying mutations involving cysteine residues. Leptin is a 16 kDa hormone synthesised by adipocytes which regulates appetite and energy expenditure at the hypothalamic level (26) , and is involved in immune modulation in that it influences the innate immune response by promoting activation of monocyte/ macrophages, chemotaxis and activation of neutrophils, and activation of natural killer cells (27) . Finck et al. have recently demonstrated that tumour necrosis factor (TNF)-α acts directly on adipocytes, thus inducing leptin through activation of TNFRSF1A (28) . In patients with TRAPS, the altered TNFRSF1A activity might be responsible for serum leptin correlation with TRAPS severity (5).
Adiponectin is a 244-residue adiposespecific protein which is produced in much greater quantities than leptin and is abundantly present in human plasma. The gene encoding adiponectin is located at chromosomal band 3q27, a susceptibility locus for diabetes and cardiovascular disease (29) . Although adiponectin was first documented to have anti-inflammatory actions on metabolic pathways and vasculature (30, 31) , it is now well-demonstrated that its pro-inflammatory effects are paradoxically more prominent than its anti-atherogenic and anti-inflammatory properties (32) . Its correlation with the presence of amyloidosis may be linked to the deterioration of renal function, and it may represent an adaptive response to the altered metabolic profile associated with high cardiovascular risk in chronic kidney disease patients (33) . TRAPS patients have been reported to have an increased risk of cardiovascular diseases such as atherosclerosis and acute myocardial infarction (AMI) (34, 35) ; our findings suggest that leptin and adiponectin might play a relevant role therein. High leptin is a significant risk factor for AMI, since it exerts many potentially atherogenic effects such as induction of endothelial dysfunction, stimulation of inflammatory reaction, oxidative stress, decrease in paraoxonase activity, platelet aggregation, migration, hypertrophy and proliferation of vascular smooth muscle cells (36) . In addition, leptin serum levels have recently been demonstrated to significantly correlate with markers of subclinical atherosclerosis (carotid artery intima-media thickness and coronary artery calcifications) (37) . Elevated adiponectin has also been shown to be significantly correlated with a higher risk of cardiovascular disease (fatal and non-fatal myocardial infarction) and coronary artery disease (38) . Further studies are needed in order to evaluate whether the types of adipokine serum level modifications we describe may have concrete repercussions on cardiovascular risk factors in TRAPS patients. Toward this end, it would be interesting to evaluate the presence of carotid artery plaque in these patients, which may be a stronger predictor of atherosclerotic disease (39) . Our study has some limitations. The lack of correlation with additional disease activity parameters might be, at least in part, due to the applied study design. This is, in fact, a cross-sectional study: it is our aim to duplicate the results in a prospective fashion, using paired analysis for each subject at different times of disease activity; repeated measurements of adipokines over time might provide additional information. Recent studies have shown that the biochemical markers of inflammation may remain elevated in TRAPS also during symptom-free intervals. For this reason, the lack of difference in adipokines serum levels, which we demonstrated in our study between TRAPS patients and healthy controls, could be better substantiated taking serum samples both during fever attacks and during fever-free periods. In addition, the numbers of participants may be too small to arrive at more significant associations, and collaborative large-scale studies are needed. Although many issues still remain hazy, increasing research efforts in the area of adipokines are gradually revealing the intricate adipokine-mediated interplay among white adipose tissue, chronic autoinflammatory disorders and cardiovascular risk. Further insights into the intimate mechanisms regulating the central and peripheral activity of adipokines might in the future generate well-supported therapeutic hypotheses, however, the rate at which their roles are being clarified makes it likely that they will become central to pharmacotherapeutic approaches in immune disorders (40, 41) .
